Navigation Links
Results of the PARIS registry Reported at TCT 2011

SAN FRANCISCO, CA WEDNESDAY, NOVEMBER 9, 2011 Non-adherence to antiplatelet therapy which prevents blood clots following percutaneous coronary intervention (PCI) was associated with higher rates of both ischemic and bleeding events at 30 days. Results of the PARIS registry were presented today at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.

Dual antiplatelet therapy (DAPT) with aspirin and a thienopyridine is the cornerstone of treatment for patients presenting with acute coronary syndromes and for patients undergoing percutaneous coronary intervention (PCI) with stents. Current guidelines recommend at least one year of DAPT for all patients following PCI with a drug-eluting stent (DES), and 30 days after a bare metal stent.

Premature discontinuation of DAPT (within the first six months after implantation of DES) has been associated with an increased risk of stent thrombosis, but the optimal duration of DAPT has not yet been precisely determined, especially with regard to second generation stents.

The PARIS Registry (Patterns of Non-Adherence to Anti-Platelet Regimens In Stented Patients: An Observational Single Arm Study) is a multicenter, multinational, observational study with an "all comers" design. The study will follow 5,033 subjects for approximately 24 months post stent implantation (bare metal and drug-eluting stents.)

The objectives of this study are to examine modes of non-adherence to DAPT in patients following stenting, and to evaluate subsequent clinical outcomes and their relation to non-adherence.

The incidence of non-adherence to DAPT in this "real world" international observational registry was 2.0% at 30-day follow-up.

In the non-adherent population at 30-days:

  • 69% had disruption of therapy - mostly due to non-compliance (61%) and bleeding event (32%)
  • 19% had interruption of DAPT - mostly due to surgery or medical procedures (67%)
  • 12% had discontinuation of therapy (recommended by physician)

"Importantly, any non-adherence (aspirin or thienopyridine non-adherence was equally distributed) was associated with higher rates of both ischemic and bleeding events at 30 days including death, myocardial infarction, definite and/or probable stent thrombosis, target vessel revascularization, and bleeding (BARC≥3)," said Roxana Mehran, MD, the co-principal investigator of the study. Dr. Mehran is Professor of Medicine at Mount Sinai School of Medicine and Director of Interventional Cardiovascular Research and Clinical Trials at the Zena and Michael A. Wiener Cardiovascular Institute. She also serves as Chief Scientific Officer of the CRF Clinical Trials Center.

"There was a six-fold increase in odds for definite or probable stent thrombosis associated with non-adherence compared to adherence to DAPT at 30 days. The two year data will be more definitive and should be able to link the patterns of non-adherence with important clinical events," Dr. Mehran said.


Contact: Judy Romero
Cardiovascular Research Foundation

Related medicine news :

1. Lincare Holdings Inc. Announces Fourth Quarter and Year Ended 2009 Financial Results
2. SXC Health Solutions to Host Fiscal 2009 Fourth Quarter and Year End Results Conference Call
3. Team Health Holdings, Inc., Announces Fourth Quarter and Fiscal 2009 Financial Results
4. First blinded study of venous insufficiency prevalence in MS shows promising results
5. NEJM Publishes Trial Results Demonstrating Bard FLAIR Endovascular Stent Graft Is Superior To Balloon Angioplasty For Failing Dialysis Grafts
6. BioMed Realty Trust Reports Fourth Quarter and Full-Year 2009 Financial Results
7. Kaiser Foundation Health Plan and Hospitals Report Fourth Quarter and Fiscal Year 2009 Financial Results
8. United American Healthcare Corporation Announces Fiscal 2010 Second Quarter Results
9. Fitness Trend Towards Online Personal Training Gets Real-World Weight Loss Results on
10. Protein Sciences Corporation Announces Profitable and Cash Flow Positive Results for 2009 and Management Realignment
11. WebMD Announces Fourth Quarter Financial Results
Post Your Comments:
(Date:11/27/2015)... ... 2015 , ... The men and women on this list ... the country. They have overseen financial turnarounds, shown commitment to their community through ... as a whole through their advocacy and professional efforts. , Becker's Hospital Review ...
(Date:11/27/2015)... San Francisco, California (PRWEB) , ... November 27, 2015 , ... ... 1969 Janis Joplin Ann Arbor Michigan boxing style concert posters. This is one of ... 1969 at the Canterbury House at the University of Michigan in Ann Arbor. The ...
(Date:11/26/2015)... ... November 26, 2015 , ... Patients at Serenity Point Recovery, ... together on Thanksgiving Day to share the things that they are most grateful ... Point YouTube channel, patients displayed what they wrote on index cards, describing the ...
(Date:11/26/2015)... ON and Cambridge, ON (PRWEB) , ... November ... ... today the availability of a real-time eReferral system for diagnostic imaging in the ... ultrasounds, X-rays, mammography, BMD and Nuclear Medicine tests directly from their electronic medical ...
(Date:11/26/2015)... ... November 26, 2015 , ... The Catalent Applied Drug Delivery ... to integrate dose form selection in early phase drug development. The first of ... and bringing together the UK’s emerging life sciences companies, corporate partners, and investors, ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... Research and Markets ( ) has announced the ... Type (Dressings, Therapy Devices, Active Wound Care), Application (Surgical ... Geography - Global Forecast to 2020" report to ... --> The purpose of this report is to ... advanced wound care market. It involves deep dive analysis ...
(Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... --> adds "Global ... and "Investigation Report on China Repaglinide ... 2021 forecasts data and information to ... . --> ...
(Date:11/26/2015)... , Nov. 26, 2015 Research and ... of the "2016 Future Horizons and Growth ... Market: Supplier Shares, Country Segment Forecasts, Competitive Intelligence, ... --> --> ... of the Italian therapeutic drug monitoring market, including ...
Breaking Medicine Technology: